HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Class-Actions Increasing As Fallout From Regulatory Action

This article was originally published in The Tan Sheet

Executive Summary

Using marketing claims that overstep cosmetic boundaries can land firms in class-action suits that sap resources and drag on for years, attorneys noted at the ACI Legal, Regulatory and Compliance Forum on Cosmetics. Speakers provided examples and tips for staying out of court.

You may also be interested in...



“Piggyback” Lawsuits Spur NAD To Clarify Purpose Of Investigations

Class-action lawsuits filed following National Advertising Division decisions raise concerns among firms participating in NAD’s self-regulatory process. The advertising industry’s voluntary self-regulation program clarifies that its findings do not indicate any laws have been violated.

FDA Warning To Skin Care Firm Shows Perils Of Cosmetics-To-OTC Transition

FDA's warning letter saying skin care product firm MW Laboratories marketed unapproved new drugs illustrates the potentially perilous transition from offering cosmeceuticals to marketing OTC drugs

China Regulatory Probe Slows Nu Skin Growth After Record Year

The firm’s recent explosive growth is expected to slow substantially in the first quarter – to between 20% and 24% – but Nu Skin is confident the steps it is taking in China “make our long-term success more likely.” Analysts have faith in the firm as it works with Chinese officials to resolve an investigation into its business practices.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS123962

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel